{"entity":{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","aka":["Pancreatic cancer trials recruiting","Open pancreatic cancer trials"],"tldr":"Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for pancreatic cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.","summary":"The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming pancreatic cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed: 589 studies, of which 209 were already in the corpus, 36 were neuroendocrine-only and are left out, and 284 are carried as registry-only records linked here (163 phase 2, 72 phase 1/2, 33 phase 3 and 16 phase 2/3; 183 recruiting, 97 not yet recruiting, 4 phase 3 or 2/3 trials active but closed). Most are run from the United States (120 of the new trials) and China (119), then France, Canada, Spain, the Netherlands, South Korea, Australia, the United Kingdom and Italy. The phase 3 questions open today are perioperative against adjuvant chemotherapy for resectable disease (Alliance A021806, PREOPANC-3, NeoFOL-R, LEFT-PANC), prolonged neoadjuvant chemotherapy for borderline and locally advanced disease (ADVANTAGE), dose-escalated radiotherapy for locally advanced disease (LAP100), adjuvant chemoradiotherapy (ADJUPANC), switch maintenance (PANThEON), first-line RAS inhibition (RASolute 303, RASolute 305, RASolute 309, DAWN-303), adjuvant daraxonrasib (RASolute 304), quemliclustat (PRISM-1) and claudin 18.2 antibodies. UK hospitals appear in RASolute 303 (Torbay, Birmingham, Cambridge, Barts, the Royal Marsden, the Christie), RASolute 304 (Birmingham, Glasgow, Liverpool, the Royal Marsden, Hammersmith, the Christie), IMCODE003 (eight sites), PRISM-1, DAWN-303 (nine sites), the setidegrasib trial NCT07409272 (seven sites), the pembrolizumab and olaparib trial NCT05093231 (15 sites, led from Cambridge), STARPAC2 (Barts) and the DETERMINE platform. The ISRCTN registry lists 176 hits for pancreatic cancer, 97 naming the disease, most of them UK surgical, diagnostic and observational studies; the interventional UK trials with results (SCALOP, ESPAC-4, ESPAC-5, SIEGE) and the open ones (STARPAC2, PRIMUS 001, DETERMINE) are hand-written.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov search: pancreatic cancer, interventional, phase 2 and 3, recruiting","url":"https://clinicaltrials.gov/search?cond=pancreatic%20cancer&aggFilters=phase:2%203,status:rec%20not%20act,studyType:int"},{"label":"ISRCTN registry search: pancreatic cancer","url":"https://www.isrctn.com/search?q=pancreatic+cancer"}],"tags":[],"related":[],"cancers":["pancreatic","resectable-pdac","borderline-resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["resectability","neoadjuvant-adjuvant","kras-mutation-subtypes"],"trials":["alliance-a021806","preopanc-3","nct05968326","nct07491445","nct07252232","nct07621718","nct07805954","nct06608927","nct07522073","nct07409272","starpac2","primus-001","scalop-2","precision-promise","nct06783140","nct06946420","nct05836870","nct06115499","nct07386704","nct07344220","nct06866977","nct07469956","nct07138846","nct07153289","nct07415525","nct06991491","nct07745790","nct04901741","nct07814066","nct07705074","nct07028424","nct06383078","nct07277452","nct07477418","nct06759090","nct06513455","nct05810792","nct07765836","nct07230301","nct07773363","nct06573398","nct07691593","nct06233877","nct06750861","nct07689539","nct06370754","nct07578337","nct06621095","nct06009029","nct03301805","nct06166589","nct06255912","nct07705919","nct06361030","nct07711067","nct07670312","nct07336953","nct07678593","nct07802184","nct07333287","nct07824960","nct07175389","nct07342725","nct05637567","nct06888648","nct06571461","nct06662669","nct05562297","nct06999512","nct05988372","nct07827053","nct07748611","nct07689955","nct07698613","nct07561463","nct07504263","nct07631871","nct06329947","nct07155629","nct06259058","nct06172036","nct06492941","nct04381130","nct06916975","nct06217042","nct06210360","nct06669078","nct07683221","nct06234072","nct06177522","nct07806058","nct06700603","nct07814859","nct07097064","nct07233850","nct07825753","nct07752875","nct06938503","nct07446270","nct07108504","nct06888674","nct07208539","nct06409429","nct07736612","nct07784374","nct07802418","nct07803783","nct07665684","nct07828756","nct07383922","nct07429643","nct07831330","nct07656376","nct07301229","nct07833241","nct07272109","nct06196671","nct06587061","nct06423326","nct06483555","nct07043270","nct06938282","nct04084496","nct06411795","nct07235930","nct07542002","nct03322995","nct06782932","nct07155525","nct04683315","nct07769502","nct07632118","nct05841420","nct07595835","nct04172532","nct05438459","nct07410676","nct05679583","nct07483983","nct07066995","nct07440290","nct06906562","nct07353645","nct06843551","nct06790602","nct07312422","nct06427239","nct06782412","nct06391892","nct06095141","nct06861452","nct05187338","nct06159478","nct05821556","nct06736717","nct06844422","nct05218889","nct07436741","nct06384560","nct06199895","nct06580002","nct07285044","nct06479239","nct07040228","nct06831136","nct06453486","nct05988814","nct07269626","nct07199764","nct07098598","nct05929885","nct07306286","nct06722911","nct06584227","nct06332274","nct05944237","nct07595172","nct06030622","nct06662006","nct05518903","nct06601283","nct06756074","nct05969860","nct06435260","nct07600268","nct07435038","nct06714604","nct06503146","nct07110064","nct07716228","nct05744219","nct05093231","nct05065801","nct05268692","nct04990609","nct07131514","nct03492671","nct06758544","nct05969171","nct06944106","nct06946901","nct03977233","nct07504471","nct06782685","nct06017284","nct05053971","nct03498326","nct06998940","nct07410494","nct04485286","nct03608631","nct07306273","nct06598033","nct06770452","nct06405490","nct07230509","nct04858334","nct06958328","nct06250972","nct07283705","nct04146298","nct06605430","nct05083247","nct04570943","nct07354919","nct06770439","nct06145074","nct06789679","nct05624918","nct06914674","nct06690528","nct06807437","nct06757244","nct07619521","nct06149689","nct05529940","nct05984810","nct06593431","nct05927142","nct07629609","nct05720338","nct06196788","nct06454448","nct07539155","nct07126158","nct07284277","nct05776524","nct05462496","nct05241249","nct04605913","nct06427460","nct06951997","nct06761027","nct03190941","nct07101679","nct06813079","nct04195347","nct06747845","nct07240766","nct06491472","nct03755739","nct06941857","nct06904378","nct06050317","nct07537660","nct06897644","nct07214298","nct02000089","nct06576115","nct06532617","nct07226856","nct07257523","nct07692750","nct06229340","nct06359275","nct06389760","nct05116072","nct06249321","nct06572813","nct06531278","nct03384238","nct06659705","nct06427447","nct05132504","nct06333314","nct04851119","nct06547736","nct07438106","nct07081360","nct02830724","nct07433283","nct04789486","nct03093688","nct07586813","nct06151262","nct02598349","nct04858009","nct07044453"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/pancreatic-trials-open-today/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"term":[{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/"}],"trial":[{"id":"nct06503146","kind":"trial","name":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","route":"/trials/nct06503146/"},{"id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","route":"/trials/nct07043270/"},{"id":"nct07578337","kind":"trial","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","route":"/trials/nct07578337/"},{"id":"nct07333287","kind":"trial","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","route":"/trials/nct07333287/"},{"id":"nct07814066","kind":"trial","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","route":"/trials/nct07814066/"},{"id":"nct07736612","kind":"trial","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","route":"/trials/nct07736612/"},{"id":"nct04381130","kind":"trial","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","route":"/trials/nct04381130/"},{"id":"nct07040228","kind":"trial","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07040228/"},{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","route":"/trials/nct07233850/"},{"id":"nct07301229","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct07301229/"},{"id":"nct06906562","kind":"trial","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","route":"/trials/nct06906562/"},{"id":"nct07283705","kind":"trial","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","route":"/trials/nct07283705/"},{"id":"nct07784374","kind":"trial","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","route":"/trials/nct07784374/"},{"id":"nct07438106","kind":"trial","name":"A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct07438106/"},{"id":"nct06329947","kind":"trial","name":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","route":"/trials/nct06329947/"},{"id":"nct03301805","kind":"trial","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","route":"/trials/nct03301805/"},{"id":"nct07336953","kind":"trial","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","route":"/trials/nct07336953/"},{"id":"nct07689955","kind":"trial","name":"A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer","route":"/trials/nct07689955/"},{"id":"nct06866977","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","route":"/trials/nct06866977/"},{"id":"nct06758544","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer","route":"/trials/nct06758544/"},{"id":"nct05969171","kind":"trial","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","route":"/trials/nct05969171/"},{"id":"nct07138846","kind":"trial","name":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct07138846/"},{"id":"nct07711067","kind":"trial","name":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","route":"/trials/nct07711067/"},{"id":"nct06492941","kind":"trial","name":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06492941/"},{"id":"nct07383922","kind":"trial","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","route":"/trials/nct07383922/"},{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/"},{"id":"nct07101679","kind":"trial","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","route":"/trials/nct07101679/"},{"id":"nct06453486","kind":"trial","name":"A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","route":"/trials/nct06453486/"},{"id":"nct07752875","kind":"trial","name":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","route":"/trials/nct07752875/"},{"id":"nct05624918","kind":"trial","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05624918/"},{"id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/"},{"id":"nct06151262","kind":"trial","name":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct06151262/"},{"id":"nct06944106","kind":"trial","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06944106/"},{"id":"nct07769502","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","route":"/trials/nct07769502/"},{"id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","route":"/trials/nct07803783/"},{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/"},{"id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/"},{"id":"nct07272109","kind":"trial","name":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","route":"/trials/nct07272109/"},{"id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","route":"/trials/nct06844422/"},{"id":"nct06531278","kind":"trial","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","route":"/trials/nct06531278/"},{"id":"nct06584227","kind":"trial","name":"Adebrelimab and Chidamide for Pancreatic Cancer","route":"/trials/nct06584227/"},{"id":"nct06916975","kind":"trial","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06916975/"},{"id":"nct06177522","kind":"trial","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","route":"/trials/nct06177522/"},{"id":"nct07230301","kind":"trial","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","route":"/trials/nct07230301/"},{"id":"nct06427447","kind":"trial","name":"Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)","route":"/trials/nct06427447/"},{"id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","route":"/trials/nct02830724/"},{"id":"nct03190941","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","route":"/trials/nct03190941/"},{"id":"nct07208539","kind":"trial","name":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","route":"/trials/nct07208539/"},{"id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","route":"/trials/nct06938503/"},{"id":"nct07831330","kind":"trial","name":"Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer","route":"/trials/nct07831330/"},{"id":"nct07828756","kind":"trial","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","route":"/trials/nct07828756/"},{"id":"nct06789679","kind":"trial","name":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06789679/"},{"id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/"},{"id":"nct06938282","kind":"trial","name":"An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer","route":"/trials/nct06938282/"},{"id":"nct07631871","kind":"trial","name":"An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","route":"/trials/nct07631871/"},{"id":"nct07806058","kind":"trial","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","route":"/trials/nct07806058/"},{"id":"nct06621095","kind":"trial","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","route":"/trials/nct06621095/"},{"id":"nct04858334","kind":"trial","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","route":"/trials/nct04858334/"},{"id":"nct05969860","kind":"trial","name":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","route":"/trials/nct05969860/"},{"id":"nct07537660","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel","route":"/trials/nct07537660/"},{"id":"nct07716228","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","route":"/trials/nct07716228/"},{"id":"nct07354919","kind":"trial","name":"Axelopran for Advanced Cancer in Patients Receiving Opioids","route":"/trials/nct07354919/"},{"id":"nct06483555","kind":"trial","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","route":"/trials/nct06483555/"},{"id":"nct07629609","kind":"trial","name":"BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer","route":"/trials/nct07629609/"},{"id":"nct06159478","kind":"trial","name":"Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)","route":"/trials/nct06159478/"},{"id":"nct07410494","kind":"trial","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07410494/"},{"id":"nct07226856","kind":"trial","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","route":"/trials/nct07226856/"},{"id":"nct06572813","kind":"trial","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","route":"/trials/nct06572813/"},{"id":"nct06532617","kind":"trial","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06532617/"},{"id":"nct07257523","kind":"trial","name":"Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","route":"/trials/nct07257523/"},{"id":"nct07433283","kind":"trial","name":"Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor","route":"/trials/nct07433283/"},{"id":"nct07153289","kind":"trial","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","route":"/trials/nct07153289/"},{"id":"nct06790602","kind":"trial","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct06790602/"},{"id":"nct06427460","kind":"trial","name":"Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)","route":"/trials/nct06427460/"},{"id":"nct06095141","kind":"trial","name":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","route":"/trials/nct06095141/"},{"id":"nct06199895","kind":"trial","name":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholan","route":"/trials/nct06199895/"},{"id":"nct03093688","kind":"trial","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","route":"/trials/nct03093688/"},{"id":"nct07827053","kind":"trial","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","route":"/trials/nct07827053/"},{"id":"nct06233877","kind":"trial","name":"Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer","route":"/trials/nct06233877/"},{"id":"nct06255912","kind":"trial","name":"Clinical Trial for Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06255912/"},{"id":"nct07656376","kind":"trial","name":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07656376/"},{"id":"nct05927142","kind":"trial","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","route":"/trials/nct05927142/"},{"id":"nct06234072","kind":"trial","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","route":"/trials/nct06234072/"},{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/"},{"id":"nct06690528","kind":"trial","name":"Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","route":"/trials/nct06690528/"},{"id":"nct07306286","kind":"trial","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306286/"},{"id":"nct07595835","kind":"trial","name":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer","route":"/trials/nct07595835/"},{"id":"nct06659705","kind":"trial","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","route":"/trials/nct06659705/"},{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/"},{"id":"nct07440290","kind":"trial","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","route":"/trials/nct07440290/"},{"id":"nct06333314","kind":"trial","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","route":"/trials/nct06333314/"},{"id":"nct06757244","kind":"trial","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","route":"/trials/nct06757244/"},{"id":"nct07410676","kind":"trial","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct07410676/"},{"id":"nct07108504","kind":"trial","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07108504/"},{"id":"nct05116072","kind":"trial","name":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","route":"/trials/nct05116072/"},{"id":"nct05065801","kind":"trial","name":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","route":"/trials/nct05065801/"},{"id":"nct07600268","kind":"trial","name":"Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07600268/"},{"id":"nct07446270","kind":"trial","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","route":"/trials/nct07446270/"},{"id":"nct07698613","kind":"trial","name":"EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","route":"/trials/nct07698613/"},{"id":"nct06831136","kind":"trial","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","route":"/trials/nct06831136/"},{"id":"nct07429643","kind":"trial","name":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","route":"/trials/nct07429643/"},{"id":"nct04990609","kind":"trial","name":"EUS-RFA PANCARDINAL-1 Trial","route":"/trials/nct04990609/"},{"id":"nct04485286","kind":"trial","name":"Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury","route":"/trials/nct04485286/"},{"id":"nct07097064","kind":"trial","name":"Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","route":"/trials/nct07097064/"},{"id":"nct07670312","kind":"trial","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/"},{"id":"nct06145074","kind":"trial","name":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.","route":"/trials/nct06145074/"},{"id":"nct06427239","kind":"trial","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06427239/"},{"id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","route":"/trials/nct06547736/"},{"id":"nct06593431","kind":"trial","name":"Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","route":"/trials/nct06593431/"},{"id":"nct07705074","kind":"trial","name":"FAPI PET Imaging - An Exploratory Study","route":"/trials/nct07705074/"},{"id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07235930/"},{"id":"nct05438459","kind":"trial","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","route":"/trials/nct05438459/"},{"id":"nct03498326","kind":"trial","name":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","route":"/trials/nct03498326/"},{"id":"nct06897644","kind":"trial","name":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C","route":"/trials/nct06897644/"},{"id":"nct05841420","kind":"trial","name":"Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","route":"/trials/nct05841420/"},{"id":"nct06423326","kind":"trial","name":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","route":"/trials/nct06423326/"},{"id":"nct06576115","kind":"trial","name":"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","route":"/trials/nct06576115/"},{"id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","route":"/trials/nct07802184/"},{"id":"nct07504471","kind":"trial","name":"Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metast","route":"/trials/nct07504471/"},{"id":"nct05810792","kind":"trial","name":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","route":"/trials/nct05810792/"},{"id":"nct06217042","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06217042/"},{"id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06383078/"},{"id":"nct06587061","kind":"trial","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct06587061/"},{"id":"nct07131514","kind":"trial","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct07131514/"},{"id":"nct07240766","kind":"trial","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","route":"/trials/nct07240766/"},{"id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","route":"/trials/nct06770452/"},{"id":"nct05944237","kind":"trial","name":"HTL0039732 in Participants With Advanced Solid Tumours","route":"/trials/nct05944237/"},{"id":"nct04858009","kind":"trial","name":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","route":"/trials/nct04858009/"},{"id":"nct06435260","kind":"trial","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/"},{"id":"nct07415525","kind":"trial","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","route":"/trials/nct07415525/"},{"id":"nct06770439","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct06770439/"},{"id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct07692750/"},{"id":"nct03608631","kind":"trial","name":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","route":"/trials/nct03608631/"},{"id":"nct06999512","kind":"trial","name":"Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for C","route":"/trials/nct06999512/"},{"id":"nct05744219","kind":"trial","name":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","route":"/trials/nct05744219/"},{"id":"nct07539155","kind":"trial","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","route":"/trials/nct07539155/"},{"id":"nct05518903","kind":"trial","name":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","route":"/trials/nct05518903/"},{"id":"nct07306273","kind":"trial","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306273/"},{"id":"nct06172036","kind":"trial","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","route":"/trials/nct06172036/"},{"id":"nct06513455","kind":"trial","name":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","route":"/trials/nct06513455/"},{"id":"nct05720338","kind":"trial","name":"Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?","route":"/trials/nct05720338/"},{"id":"nct06991491","kind":"trial","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","route":"/trials/nct06991491/"},{"id":"nct06491472","kind":"trial","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","route":"/trials/nct06491472/"},{"id":"nct07175389","kind":"trial","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","route":"/trials/nct07175389/"},{"id":"nct07353645","kind":"trial","name":"KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer","route":"/trials/nct07353645/"},{"id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/"},{"id":"nct07312422","kind":"trial","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","route":"/trials/nct07312422/"},{"id":"nct06229340","kind":"trial","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","route":"/trials/nct06229340/"},{"id":"nct06782685","kind":"trial","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","route":"/trials/nct06782685/"},{"id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","route":"/trials/nct06571461/"},{"id":"nct07542002","kind":"trial","name":"Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan","route":"/trials/nct07542002/"},{"id":"nct06391892","kind":"trial","name":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","route":"/trials/nct06391892/"},{"id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","route":"/trials/nct07199764/"},{"id":"nct06747845","kind":"trial","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","route":"/trials/nct06747845/"},{"id":"nct06605430","kind":"trial","name":"Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","route":"/trials/nct06605430/"},{"id":"nct07066995","kind":"trial","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07066995/"},{"id":"nct07344220","kind":"trial","name":"Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","route":"/trials/nct07344220/"},{"id":"nct06759090","kind":"trial","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06759090/"},{"id":"nct05929885","kind":"trial","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","route":"/trials/nct05929885/"},{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/"},{"id":"nct06761027","kind":"trial","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","route":"/trials/nct06761027/"},{"id":"nct06149689","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","route":"/trials/nct06149689/"},{"id":"nct06249321","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","route":"/trials/nct06249321/"},{"id":"nct05462496","kind":"trial","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","route":"/trials/nct05462496/"},{"id":"nct07802418","kind":"trial","name":"Molecularly Tailored Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07802418/"},{"id":"nct06782412","kind":"trial","name":"Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif","route":"/trials/nct06782412/"},{"id":"nct04146298","kind":"trial","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","route":"/trials/nct04146298/"},{"id":"nct04605913","kind":"trial","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","route":"/trials/nct04605913/"},{"id":"nct06662006","kind":"trial","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic","route":"/trials/nct06662006/"},{"id":"nct06405490","kind":"trial","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","route":"/trials/nct06405490/"},{"id":"nct06669078","kind":"trial","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","route":"/trials/nct06669078/"},{"id":"nct07595172","kind":"trial","name":"NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","route":"/trials/nct07595172/"},{"id":"nct04789486","kind":"trial","name":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","route":"/trials/nct04789486/"},{"id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","route":"/trials/nct06941857/"},{"id":"nct07824960","kind":"trial","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","route":"/trials/nct07824960/"},{"id":"nct05268692","kind":"trial","name":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","route":"/trials/nct05268692/"},{"id":"nct05132504","kind":"trial","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05132504/"},{"id":"nct07691593","kind":"trial","name":"Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","route":"/trials/nct07691593/"},{"id":"nct07155629","kind":"trial","name":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","route":"/trials/nct07155629/"},{"id":"nct06384560","kind":"trial","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","route":"/trials/nct06384560/"},{"id":"nct07081360","kind":"trial","name":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","route":"/trials/nct07081360/"},{"id":"nct05562297","kind":"trial","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct05562297/"},{"id":"nct05529940","kind":"trial","name":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","route":"/trials/nct05529940/"},{"id":"nct06370754","kind":"trial","name":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","route":"/trials/nct06370754/"},{"id":"nct07386704","kind":"trial","name":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","route":"/trials/nct07386704/"},{"id":"nct06409429","kind":"trial","name":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06409429/"},{"id":"nct06389760","kind":"trial","name":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06389760/"},{"id":"nct07277452","kind":"trial","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct07277452/"},{"id":"nct05984810","kind":"trial","name":"NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101","route":"/trials/nct05984810/"},{"id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","route":"/trials/nct04901741/"},{"id":"nct06196671","kind":"trial","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196671/"},{"id":"nct06904378","kind":"trial","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06904378/"},{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/"},{"id":"nct03322995","kind":"trial","name":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","route":"/trials/nct03322995/"},{"id":"nct07098598","kind":"trial","name":"Pancreatic Cancer Diagnosis With FAPI-PET Imaging","route":"/trials/nct07098598/"},{"id":"nct07230509","kind":"trial","name":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","route":"/trials/nct07230509/"},{"id":"nct03384238","kind":"trial","name":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","route":"/trials/nct03384238/"},{"id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","route":"/trials/nct07028424/"},{"id":"nct06359275","kind":"trial","name":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","route":"/trials/nct06359275/"},{"id":"nct07477418","kind":"trial","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","route":"/trials/nct07477418/"},{"id":"nct07214298","kind":"trial","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07214298/"},{"id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","route":"/trials/nct05093231/"},{"id":"nct05637567","kind":"trial","name":"Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","route":"/trials/nct05637567/"},{"id":"nct06210360","kind":"trial","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","route":"/trials/nct06210360/"},{"id":"nct06888674","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","route":"/trials/nct06888674/"},{"id":"nct06888648","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","route":"/trials/nct06888648/"},{"id":"nct07504263","kind":"trial","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","route":"/trials/nct07504263/"},{"id":"nct06030622","kind":"trial","name":"Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer","route":"/trials/nct06030622/"},{"id":"nct06861452","kind":"trial","name":"Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","route":"/trials/nct06861452/"},{"id":"nct06454448","kind":"trial","name":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P","route":"/trials/nct06454448/"},{"id":"nct07342725","kind":"trial","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","route":"/trials/nct07342725/"},{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/"},{"id":"preopanc-3","kind":"trial","name":"PREOPANC-3","route":"/trials/preopanc-3/"},{"id":"nct05083247","kind":"trial","name":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05083247/"},{"id":"nct05679583","kind":"trial","name":"Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer","route":"/trials/nct05679583/"},{"id":"primus-001","kind":"trial","name":"PRIMUS 001","route":"/trials/primus-001/"},{"id":"nct07825753","kind":"trial","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","route":"/trials/nct07825753/"},{"id":"nct02598349","kind":"trial","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","route":"/trials/nct02598349/"},{"id":"nct07269626","kind":"trial","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","route":"/trials/nct07269626/"},{"id":"nct04683315","kind":"trial","name":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","route":"/trials/nct04683315/"},{"id":"nct06750861","kind":"trial","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","route":"/trials/nct06750861/"},{"id":"nct06951997","kind":"trial","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","route":"/trials/nct06951997/"},{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/"},{"id":"nct06250972","kind":"trial","name":"Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer","route":"/trials/nct06250972/"},{"id":"nct07632118","kind":"trial","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","route":"/trials/nct07632118/"},{"id":"nct06573398","kind":"trial","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","route":"/trials/nct06573398/"},{"id":"nct06411795","kind":"trial","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","route":"/trials/nct06411795/"},{"id":"nct06756074","kind":"trial","name":"Reinforced Pancreaticojejunostomy With or Without glubran2","route":"/trials/nct06756074/"},{"id":"nct06580002","kind":"trial","name":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","route":"/trials/nct06580002/"},{"id":"nct07814859","kind":"trial","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","route":"/trials/nct07814859/"},{"id":"nct07773363","kind":"trial","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","route":"/trials/nct07773363/"},{"id":"nct07044453","kind":"trial","name":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","route":"/trials/nct07044453/"},{"id":"nct07586813","kind":"trial","name":"Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors","route":"/trials/nct07586813/"},{"id":"nct07561463","kind":"trial","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","route":"/trials/nct07561463/"},{"id":"nct07745790","kind":"trial","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07745790/"},{"id":"nct07665684","kind":"trial","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","route":"/trials/nct07665684/"},{"id":"nct06009029","kind":"trial","name":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","route":"/trials/nct06009029/"},{"id":"nct07683221","kind":"trial","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","route":"/trials/nct07683221/"},{"id":"scalop-2","kind":"trial","name":"SCALOP-2","route":"/trials/scalop-2/"},{"id":"nct06700603","kind":"trial","name":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","route":"/trials/nct06700603/"},{"id":"nct06166589","kind":"trial","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","route":"/trials/nct06166589/"},{"id":"nct06946420","kind":"trial","name":"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy","route":"/trials/nct06946420/"},{"id":"nct04570943","kind":"trial","name":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04570943/"},{"id":"nct06050317","kind":"trial","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/"},{"id":"nct07748611","kind":"trial","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","route":"/trials/nct07748611/"},{"id":"nct06714604","kind":"trial","name":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","route":"/trials/nct06714604/"},{"id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/"},{"id":"nct06259058","kind":"trial","name":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06259058/"},{"id":"nct07126158","kind":"trial","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","route":"/trials/nct07126158/"},{"id":"nct05241249","kind":"trial","name":"Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma","route":"/trials/nct05241249/"},{"id":"nct07483983","kind":"trial","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","route":"/trials/nct07483983/"},{"id":"nct06722911","kind":"trial","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","route":"/trials/nct06722911/"},{"id":"nct05776524","kind":"trial","name":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","route":"/trials/nct05776524/"},{"id":"nct07435038","kind":"trial","name":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct07435038/"},{"id":"nct04195347","kind":"trial","name":"Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","route":"/trials/nct04195347/"},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/"},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/"},{"id":"nct06479239","kind":"trial","name":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","route":"/trials/nct06479239/"},{"id":"nct06783140","kind":"trial","name":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","route":"/trials/nct06783140/"},{"id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/"},{"id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/"},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/"},{"id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","route":"/trials/nct06998940/"},{"id":"nct05988372","kind":"trial","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","route":"/trials/nct05988372/"},{"id":"nct06361030","kind":"trial","name":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","route":"/trials/nct06361030/"},{"id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","route":"/trials/nct07833241/"},{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/"},{"id":"nct07436741","kind":"trial","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","route":"/trials/nct07436741/"},{"id":"nct07469956","kind":"trial","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","route":"/trials/nct07469956/"},{"id":"nct06914674","kind":"trial","name":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","route":"/trials/nct06914674/"},{"id":"nct04851119","kind":"trial","name":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","route":"/trials/nct04851119/"},{"id":"nct05836870","kind":"trial","name":"Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05836870/"},{"id":"nct05053971","kind":"trial","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","route":"/trials/nct05053971/"},{"id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct06958328/"},{"id":"nct04172532","kind":"trial","name":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04172532/"},{"id":"nct07619521","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07619521/"},{"id":"nct03492671","kind":"trial","name":"Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","route":"/trials/nct03492671/"},{"id":"nct06017284","kind":"trial","name":"Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer","route":"/trials/nct06017284/"},{"id":"nct07285044","kind":"trial","name":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients","route":"/trials/nct07285044/"},{"id":"nct02000089","kind":"trial","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","route":"/trials/nct02000089/"},{"id":"nct06843551","kind":"trial","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","route":"/trials/nct06843551/"},{"id":"nct06115499","kind":"trial","name":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","route":"/trials/nct06115499/"},{"id":"nct06946901","kind":"trial","name":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a","route":"/trials/nct06946901/"},{"id":"nct06332274","kind":"trial","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","route":"/trials/nct06332274/"},{"id":"nct07155525","kind":"trial","name":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","route":"/trials/nct07155525/"},{"id":"nct03755739","kind":"trial","name":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","route":"/trials/nct03755739/"},{"id":"nct06196788","kind":"trial","name":"Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196788/"},{"id":"nct05988814","kind":"trial","name":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Li","route":"/trials/nct05988814/"},{"id":"nct07689539","kind":"trial","name":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07689539/"},{"id":"nct05187338","kind":"trial","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","route":"/trials/nct05187338/"},{"id":"nct07284277","kind":"trial","name":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","route":"/trials/nct07284277/"},{"id":"nct03977233","kind":"trial","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","route":"/trials/nct03977233/"},{"id":"nct06813079","kind":"trial","name":"Using Tumor Models to Determine Treatments","route":"/trials/nct06813079/"},{"id":"nct05821556","kind":"trial","name":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","route":"/trials/nct05821556/"},{"id":"nct07765836","kind":"trial","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","route":"/trials/nct07765836/"},{"id":"nct06601283","kind":"trial","name":"Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer","route":"/trials/nct06601283/"},{"id":"nct06598033","kind":"trial","name":"Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer","route":"/trials/nct06598033/"},{"id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","route":"/trials/nct06662669/"}]}}